HUTCHMED (China) Limited HCM
Set alert
At close
Pre-market · Nov 3, 4:43 AM ET
- YTD
- -0.45%
- 1 year
- -9.60%
- Open
- 13.23
- Prev close
- 13.15
- Mkt cap
- 2.31B
- Vol
- 47.96K
- Avg vol
- 66.77K
- EPS
- 0.10
- P/E
- 132.70
- Div yield
- 0.00%
More statistics
- Low
- 13.22
- High
- 13.46
- Forward P/E
- 51.19
- Beta
- 0.49
- Short ratio
- 4.66
- Inst. own
- 2.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 4, 2027
- 50-d avg
- 13.65
- 200-d avg
- 13.22
- 1y target
- 20.59
2Y chart
Events in this range
- Jul 2, 2025Earnings: 1.35; estimate -0.31695; surprise 525.93%
- Jul 22, 2025Rating: B of A Securities · Buy → Buy
- Aug 7, 2025Earnings: 2.6; estimate 1.46; surprise 78.08%
- Sep 22, 2025Downgrade: Morgan Stanley · Equal-Weight → Underweight
- Mar 5, 2026Earnings: 0.0005; estimate 2.5; surprise -99.98%
- Mar 10, 2026Rating: B of A Securities · Buy → Buy
- Jul 2, 2026Earnings: 0.046; estimate -0.35806; surprise 112.85%
- Jul 7, 2026Rating: B of A Securities · Buy → Buy
- Jul 23, 2026Rating: Goldman Sachs · Neutral → Neutral
- Jul 30, 2026Earnings: 0.046; estimate 0.145; surprise -68.28%
Signals (98)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2026 | 19 hours ago |
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bearish | Oct 28, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| MACD: Buy Signal | Sep 3, 2026 | 2 months ago |
| RSI: Overbought | Sep 3, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| SMA: Bullish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
Newest 20 of 98.
Key statistics
- Market cap
- 2.31B
- Enterprise value
- 1.02B
- Trailing P/E
- 132.70
- Forward P/E
- 51.19
- PEG ratio
- 0.00
- Price / sales
- 4.20
- Price / book
- 1.83
- EPS (TTM)
- 0.10
- Beta
- 0.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3.26%
- Revenue (TTM)
- 549.12M
- Revenue growth
- 0.20%
- Free cash flow
- -18.88M
- Total cash
- 1.38B
- Total debt
- 94.51M
- Return on equity
- 1.46%
- Shares outstanding
- 173.81M
- Short % of float
- 0.25%
- 50-day average
- 13.65
- 200-day average
- 13.22
Analyst view
Consensus: strong buy
- Target (low)
- 13.60
- Target (mean)
- 20.59
- Target (high)
- 33.27
- Strong buy1
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | 0.21 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.145 | 0.046 | -0.10 | -68.28% |
| Jul 2, 2026 | Mar 31, 2026 | -0.35806 | 0.046 | +0.40 | +112.85% |
| Mar 5, 2026 | Dec 31, 2025 | 2.50 | 0.0005 | -2.50 | -99.98% |
| Aug 7, 2025 | Jun 30, 2025 | 1.46 | 2.60 | +1.14 | +78.08% |
| Jul 2, 2025 | Mar 31, 2025 | -0.31695 | 1.35 | +1.67 | +525.93% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 7, 2026 | B of A Securities | main | Buy | Buy |
| Mar 10, 2026 | B of A Securities | main | Buy | Buy |
| Sep 22, 2025 | Morgan Stanley | down | Equal-Weight | Underweight |
| Jul 22, 2025 | B of A Securities | main | Buy | Buy |
| Aug 1, 2024 | Goldman Sachs | main | Neutral | Neutral |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong
- Website
- hutch-med.com
News
- HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
- Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
- Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity
- HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
- HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned
- HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer
Your note
Sign in to keep a note on HCM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Schroder Investment Management Group | 0.85% | 1,477,494 | 19.61M | Jun 29, 2026 |
| Allianz Asset Management GmbH | 0.39% | 674,511 | 8.95M | Jun 29, 2026 |
| State Street Corporation | 0.18% | 313,611 | 4.16M | Jun 29, 2026 |
| Aia Group Ltd | 0.15% | 266,658 | 3.54M | Sep 29, 2026 |
| M&G Plc | 0.14% | 242,791 | 3.22M | Jun 29, 2026 |
| Amundi | 0.12% | 204,385 | 2.71M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.05% | 84,097 | 1.12M | Jul 30, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E | 0.04% | 71,242 | 945.38K | Sep 29, 2026 |
| SPDR-EUROPE-SSgA SPDR ETFS Europe I-State Street SPDR MSCI Emerging Ma | 0.03% | 44,991 | 597.03K | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.01% | 16,399 | 217.61K | Aug 30, 2026 |
| Dimensional ETF Trust-Dimensional World ex U.S. Core Equity 2 ETF | 0.00% | 2,110 | 28.00K | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional Emerging Markets Core Equity 2 ETF | 0.00% | 5,574 | 73.97K | Jul 30, 2026 |